Androgen profile through life in women with polycystic ovary syndrome: A nordic multicenter collaboration study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3400-3407

  Pinola, Pekka ^a   Piltonen, Terhi T ^a   Puurunen, Johanna ^a   Vanky, Eszter ^c,d   Sundström Poromaa, Inger ^e   Stener Victorin, Elisabet ^f   Ruokonen, Aimo ^b   Puukka, Katri ^b   Tapanainen, Juha S ^a,b,g   Morin Papunen, Laure C ^a,b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e UPPSALA UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGE; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MENOPAUSE; MENSTRUAL CYCLE; MULTICENTER STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX HORMONE DETERMINATION; TESTOSTERONE BLOOD LEVEL; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPLICATION; HYPERANDROGENISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANDROGENS; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERANDROGENISM; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; YOUNG ADULT;

EID: 84941730251     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2123     Document Type: Article

References (39)

1. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950womenreferred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91(1):2- 6.
2. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13): 853-861.
3. March WA, Moore VM, Willson KJ, Phillips DI,NormanRJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25(2):544-551
4. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453-462.
5. Wild RA, Umstot ES, Andersen RN, Ranney GB, Givens JR. Androgen parameters and their correlation with body weight in one hundred thirty-eight women thought to have hyperandrogenism. Am J Obstet Gynecol. 1983;146(6):602-606.
6. Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod. 1997;12(5):905-909.
7. Goodarzi MO, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Steroid Biochem Mol Biol. 2015;145:213-225.
8. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the journal of clinical endocrinology and metabolism. J Clin Endocrinol Metab. 2013;98(10):3971-3973.
9. Janse F, Eijkemans MJ, Goverde AJ, et al. Assessment of androgen concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur J Endocrinol. 2011;165(6):925-933.
10. Cho LW, Kilpatrick ES, Jayagopal V, Diver MJ, Atkin SL. Biological variation of total testosterone, free androgen index and bioavailable testosterone in polycystic ovarian syndrome: Implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxf). 2008;68(3): 390-394.
11. Pinola P, Lashen H, Bloigu A, et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod. 2012;27(11):3279-3286.
12. Overlie I, Moen MH, Morkrid L, Skjaeraasen JS, Holte A. The endocrine transition around menopause-a five years prospective study with profiles of gonadotropins, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand. 1999; 78(7):642-647.
13. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an endocrine society position statement. J Clin Endocrinol Metab. 2007;92(2):405-413.
14. Shea JL, Wongt PY, Chen Y. Free testosterone: clinical utility and important analytical aspects of measurement. Adv Clin Chem. 2014;63:59-84.
15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
16. Hudecova M, Holte J, Olovsson M, Sundstrom Poromaa I. Longterm follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Hum Reprod. 2009;24(5): 1176-1183.
17. Piltonen T, Koivunen R, Perheentupa A, Morin-Papunen L, Ruokonen A, Tapanainen JS. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(8):3769-3775.
18. Stener-Victorin E,HolmG, Labrie F, Nilsson L, Janson PO, Ohlsson C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab. 2010;95(2):810-819.
19. Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011;96(3):623-631.
20. Winters SJ, Talbott E, Guzick DS, Zborowski J,McHughKP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000;73(4):724-729.
21. Liang SJ, Hsu CS, Tzeng CR, Chen CH, Hsu MI. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Hum Reprod. 2011;26(12):3443-3449.
22. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15(6):1266-1274.
23. Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94(6):1973-1978.
24. Piltonen T, Puurunen J, Hedberg P, et al. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study. Hum Reprod. 2012; 27(10):3046-3056.
25. Vanky E, Kjotrod S, Salvesen KA, Romundstad P, Moen MH, Carlsen SM. Clinical, biochemical and ultrasonographic characteristics of Scandinavian women with PCOS. Acta Obstet Gynecol Scand. 2004;83(5):482-486.
26. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672.
27. Johnstone EB, Davis G, Zane LT, Cedars MI, Huddleston HG. Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: findings in an obese, united states population. Gynecol Endocrinol. 2012;28(10):819-822.
28. Dokras A. Mood and anxiety disorders in women with PCOS. Steroids. 2012;77(4):338-341.
29. Livadas S, Chaskou S, Kandaraki AA, et al. Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2011;75(5):698-703.
30. Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertilewomenof reproductive years. Eur J Endocrinol. 2001;145(6):749-755.
31. Hudecova M, Holte J, Moby L, et al. Androgen levels, insulin sensitivity, and early insulin response in women with polycystic ovary syndrome: A long-term follow-up study. Fertil Steril. 2011;95(3): 1146-1148.
32. Purifoy FE, Koopmans LH, Tatum RW. Steroid hormones and aging: free testosterone, testosterone and androstenedione in normal females aged 20-87 years. Hum Biol. 1980;52(2):181-191.
33. Ruutiainen K, Erkkola R, Gronroos MA, Kaihola HL. Androgen parameters in hirsute women: correlations with body mass index and age. Fertil Steril. 1988;50(2):255-259.
34. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000;15(1):24-28.
35. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85(8): 2832-2838.
36. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update. 2007;13(6):559-565.
37. Schmidt J, Brannstrom M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011; 96(7):2178-2185.
38. Cao YK, Zhang SF, Zou SE, Xia X, Xu LN. Study on relationship between endogenous androgens and insulin resistance at the different stages of postmenopause. Zhonghua Fu Chan Ke Za Zhi. 2013; 48(10):740-744.
39. Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011;96(6): 1827-1834.